Paolo Ascierto

178PUBLICATIONS
676CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyMolecular targetsPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (178)

|Oct 01, 2026
Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).

|Sep 22, 2026
Transcriptomic Plasticity and Its Spatial Architecture Shape Melanoma Response to Immunotherapy and Its Combination With BRAF/MEKi.

|Aug 12, 2026
COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.

|Aug 11, 2026
Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial.

|Aug 04, 2026
Circulating thymidine kinase activity predicts survival and optimal treatment sequencing in BRAF-mutated metastatic melanoma in the SECOMBIT trial.

|Jul 02, 2026
Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years.

Pageof 30

Frequent Collaborators

35 joint publications

Georgina V Long

33 joint publications

Dirk Schadendorf

24 joint publications

Caroline Robert

24 joint publications

Reinhard Dummer